Young Adult Insulin Resistance Predicts Higher Risk of Heart Disease in Midlife

Insulin resistance in young adulthood predicts heart disease decades later, with metabolic syndrome in midlife explaining nearly two-thirds of that risk, MedPage Today reported.

The finding comes from the CARDIA cohort, which has tracked more than 3,600 people since they were 18 to 30 years old in 1985 and 1986.

By year 35 of the study — when participants were 53 to 65 — those who had insulin resistance at baseline faced a 50 percent higher risk of atherosclerotic cardiovascular disease (risk ratio 1.50, 95% CI 1.13–2.01), according to the analysis led by Chuyue Wu, MD, PhD, of the UCLA Fielding School of Public Health and published in JACC: Advances.

“These findings have potential implications for early cardiovascular prevention by suggesting that IR [insulin resistance] in young adulthood may signal an adverse CKM [cardiovascular-kidney-metabolic] trajectory before conventional cardiometabolic risk factors become fully established,” Wu and colleagues wrote.

“Young adulthood is therefore not a cardiovascular waiting room; it is a period when cardiometabolic trajectories are being established.”

— Amier Haidar, MD, MPH, McGovern Medical School, and Leonardo Roever, MHS, PhD, Brazilian Evidence-Based Health Network, in an accompanying editorial

Researchers found that 63.4 percent of the link between early insulin resistance and later heart disease was mediated through metabolic syndrome at the year-20 mark (indirect risk ratio 1.29, 95% CI 1.13–1.48). In other words, the clustering of abdominal obesity, high triglycerides, low HDL cholesterol, elevated blood pressure, and rising glucose in midlife forms the bridge between early metabolic dysfunction and later cardiovascular events.

“The substantial mediation through midlife MetS further identifies the clustering of abnormalities in adiposity, blood pressure, glucose, and lipids as a potentially important intermediate stage linking early IR to later ASCVD,” the study authors said.

Insulin resistance was defined indirectly using a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score at or above the 75th percentile (≥2.67) after a 12-hour fast. That is not the gold-standard hyperinsulinemic-euglycemic clamp, and fasting insulin is not routinely measured in clinical practice. The authors also acknowledged they did not account for changes in metabolic syndrome status before or after year 20, and residual confounding is possible in any observational study.

“Although the findings support closer cardiometabolic surveillance among young adults with IR, further research is needed to determine whether HOMA-IR improves risk prediction beyond routinely measured clinical factors, develop practical approaches for identifying IR when fasting insulin is unavailable, and test whether preventing or delaying progression to MetS reduces subsequent ASCVD risk,” Wu’s group urged.

The editorial by Haidar and Roever argues the immediate implication is not ordering HOMA-IR on every twenty-something. It is recognizing the direction of travel: a young adult with expanding waist circumference, creeping blood pressure, rising triglycerides, and worsening glycemia should not need to hit three formal metabolic-syndrome criteria before clinicians act.

“For current practice, the most important implication is therefore not a new laboratory test. It is a new sense of urgency,” the editorialists stressed.

The UCLA Fielding School of Public Health, where lead author Chuyue Wu, MD, PhD, is based, was founded in 1961 and received a $50 million gift from the Fielding family in 2012 that renamed the school. The graduate school now has nearly 1,000 students from 25 countries and 247 faculty members, and was ranked sixth in the nation by U.S. News & World Report in 2026.

CARDIA enrolled 3,622 participants (mean baseline age 25, 45 percent men, 47 percent Black) across four U.S. centers. This analysis included those who remained free of ASCVD through year 20 — more than 3,000 people — of whom one in four had insulin resistance at baseline.